Skip to product information
HEMORPHIN-7
HEMORPHIN-7
Reduces Blood Pressure
Hemorphin-7 is a hemorphin peptide, an endogenous opioid peptide derived from
the chain of hemoglobin. Hemorphin peptides exhibit antinociceptive and
antihypertensive activities, activating opioid receptors and inhibiting angiotensinconverting enzyme (ACE).
It binds to the Amgiotensin receptor triggering multiple effects including cellular
prolifearation, preferentially interacts with delta and kappa receptors. It protentiates
the activity of bradykirin causing a decrease in blood pressure.
Benefits:
Increase the blood plasma
levels of immunoreactive
hemorphin-7
• Anti-inflammatory response
in acute and chronic injuries
• Reduces Blood Pressure
• Supports oxygen transport
from lung to various
peripheral tissues
• Reduce stiffness and aids in
flexibilty
Hemorphin-7 (HE7)
Purity: > 95%
Molecular Formula: C49H64N12O11 Molecular Weight: 997.110
Sequence (three-letter code): {TYR}{PRO}{TRP}{THR}{GLN}{ARG}{PHE}
Hemorphins are opioid peptides derived by proteolysis from hemoglobin. Their sequences are
identical in several mammalian species including horses and camels. LVV-hemorphin 7
(LVVYPWTQRF) binds strongly to the Angiotensin IV (AT4) receptors in the brain. The AT4
receptors is an integral membrane aminopeptidase also as IRAP (insulin-regulated membrane
aminopeptidase). LVV-hemorphin 7 and AT4 are not substrates but rather inhibitors of the AT4
(IRAP) receptor. Both promote learning and memory and reverse amnesia in animal models.
Elevated serum levels of LVV Hemorphin 7 have also been documented in animals associated with
an increased expression of Cathespins B and D.
ADMINISTRATION AND DOSAGE
Use 1 vial mixed with 2.5ml sterile water, sub-contaneus (under the skin). For best results use 1x
5mg vial every 5 days for 6 treatments.
INGREDIENTS
6x5mg HEMORPHIN-7 (99%).
STORAGE
Keep Refrigerated when possible and out of direct sunlight.
Clinical Research
In the current study, a series of alanine-substituted and N- or C-terminally modified analogs of LVVhemorphin-7 were evaluated for their abilities to compete for 125I-Ang IV binding in horse adrenal
and cerebellar membranes.
Selected analogs were also analyzed for binding to recombinant human IRAP and inhibition of
IRAP aminopeptidase activity. C-Terminal deletions of LVV-hemorphin-7 resulted in modest
changes in affinity for IRAP, whereas deletion of the first three N-terminal residues abolished
binding. Monosubstitutions of Tyr4 and Trp6 with alanine resulted in a 10-fold reduction in affinity.
Competition binding studies using recombinant horse IRAP demonstrated the same rank order of
affinity as obtained for the ovine tissues. All LVV-hemorphin-7 analogs tested, except for Leu-ValVal-Tyr, inhibit the cleavage of the synthetic substrate, leucine -naphthylamide, by IRAP,with Ki
values between 56 and 620 nM. We find that the Val3 residue is crucial for LVV-hemorphin-7
binding to IRAP, whereas the C-terminal domain seems to play a minor role. The current study
highlights the minimal residues necessary for binding and inhibition of IRAP and provides a basis to
design peptidomimetic analogs for experimental and potentially clinical use.
Hemorphin-7 is a hemorphin peptide, an endogenous opioid peptide derived from
the chain of hemoglobin. Hemorphin peptides exhibit antinociceptive and
antihypertensive activities, activating opioid receptors and inhibiting angiotensinconverting enzyme (ACE).
It binds to the Amgiotensin receptor triggering multiple effects including cellular
prolifearation, preferentially interacts with delta and kappa receptors. It protentiates
the activity of bradykirin causing a decrease in blood pressure.
Benefits:
Increase the blood plasma
levels of immunoreactive
hemorphin-7
• Anti-inflammatory response
in acute and chronic injuries
• Reduces Blood Pressure
• Supports oxygen transport
from lung to various
peripheral tissues
• Reduce stiffness and aids in
flexibilty
Hemorphin-7 (HE7)
Purity: > 95%
Molecular Formula: C49H64N12O11 Molecular Weight: 997.110
Sequence (three-letter code): {TYR}{PRO}{TRP}{THR}{GLN}{ARG}{PHE}
Hemorphins are opioid peptides derived by proteolysis from hemoglobin. Their sequences are
identical in several mammalian species including horses and camels. LVV-hemorphin 7
(LVVYPWTQRF) binds strongly to the Angiotensin IV (AT4) receptors in the brain. The AT4
receptors is an integral membrane aminopeptidase also as IRAP (insulin-regulated membrane
aminopeptidase). LVV-hemorphin 7 and AT4 are not substrates but rather inhibitors of the AT4
(IRAP) receptor. Both promote learning and memory and reverse amnesia in animal models.
Elevated serum levels of LVV Hemorphin 7 have also been documented in animals associated with
an increased expression of Cathespins B and D.
ADMINISTRATION AND DOSAGE
Use 1 vial mixed with 2.5ml sterile water, sub-contaneus (under the skin). For best results use 1x
5mg vial every 5 days for 6 treatments.
INGREDIENTS
6x5mg HEMORPHIN-7 (99%).
STORAGE
Keep Refrigerated when possible and out of direct sunlight.
Clinical Research
In the current study, a series of alanine-substituted and N- or C-terminally modified analogs of LVVhemorphin-7 were evaluated for their abilities to compete for 125I-Ang IV binding in horse adrenal
and cerebellar membranes.
Selected analogs were also analyzed for binding to recombinant human IRAP and inhibition of
IRAP aminopeptidase activity. C-Terminal deletions of LVV-hemorphin-7 resulted in modest
changes in affinity for IRAP, whereas deletion of the first three N-terminal residues abolished
binding. Monosubstitutions of Tyr4 and Trp6 with alanine resulted in a 10-fold reduction in affinity.
Competition binding studies using recombinant horse IRAP demonstrated the same rank order of
affinity as obtained for the ovine tissues. All LVV-hemorphin-7 analogs tested, except for Leu-ValVal-Tyr, inhibit the cleavage of the synthetic substrate, leucine -naphthylamide, by IRAP,with Ki
values between 56 and 620 nM. We find that the Val3 residue is crucial for LVV-hemorphin-7
binding to IRAP, whereas the C-terminal domain seems to play a minor role. The current study
highlights the minimal residues necessary for binding and inhibition of IRAP and provides a basis to
design peptidomimetic analogs for experimental and potentially clinical use.
- Regular price
- 10.000 KWD
- Unit price
- per
Tax included.
Couldn't load pickup availability.